Vivian Adamski^*, Anne Dorothée Schmitt^*, Charlotte Flüh^*, Michael Synowitz^*, Kirsten Hattermann^†1, Janka Held-Feindt^*1

Oncology Research, Vol.25, No.3, pp. 341-353, 2017, DOI:10.3727/096504016X14737243054982

Abstract Gliomas are the most common primary brain tumors. The most malignant form, the glioblastoma multiforme (GBM; WHO IV), is characterized by an invasive phenotype, which enables the tumor cells to infiltrate into adjacent brain tissue. When investigating GBM migration and invasion properties in vitro, in most cases GBM cell lines were analyzed. Comprehensive investigations focusing on progression-dependent characteristics of migration processes using fresh human glioma samples of different malignancy grades do not exist. Thus, we isolated fast-migrating tumor cells from fresh human glioma samples of different malignancy grades (astrocytomas WHO grade II, grade III, GBM,… More >

ASPASIA MANTA¹, SPYRIDON KAZANAS², STEFANOS KARAMAROUDIS³, HELEN GOGAS², DIMITRIOS C. ZIOGAS^2,*

Oncology Research, Vol.30, No.5, pp. 211-219, 2022, DOI:10.32604/or.2022.026913

Abstract Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis… More >

F. Castinetti, A. Barlier, F. Sebag, D. Taieb

Oncologie, Vol.21, No.2, pp. 105-111, 2019, DOI:10.3166/onco-2019-0050

Abstract Pheochromocytoma and paraganglioma are tumors leading to increased morbidity and mortality. Over the last 20 years, several major advances allowed a better characterization of these tumors, either from an imaging or from a genetic viewpoint. This is especially the case for the hereditary characteristics of these tumors, as roughly 20 new genes have been identified. This is why the initial steps of the management of a pheochromocytoma and/or a paraganglioma now require a dedicated tertiary referral center. The aim of this review is to depict the diagnostic steps of these tumors, so as to allow… More >